MC4R and Obesity: It has been found that dolutegravir (DTG) has a potential for inhibiting melanotropin (MSH) binding to melanocortin 4 receptor (MC4R), which affects leptin signalling responsible for food intake (its deficiency is linked with monogenic obesity) [14,39].